Alvogen to Acquire Assertio’s Gralise (gabapentin) for $127.5M

 Alvogen to Acquire Assertio’s Gralise (gabapentin) for $127.5M

Alvogen to Acquire Assertio’s Gralise (gabapentin) for $127.5M

Shots:

  • Assertio to receive $127.5M including $75M up front in cash and $52.5M as royalties when Gralise net sales reach $75M while Alvogen will get all responsibilities related to the product. The transaction is expected to be close in Jan’2020
  • The acquisition allows Assertio to focus on its growth product, Cambia and Zipsor and improve its business development opportunities with the strengthening of its balance sheet. Assertio will provide an update on the financial impact of the sale of Gralise, following the closure of the transaction
  • Gralise is a prescription therapy indicated to treat pain after shingles, or postherpetic neuralgia (PHN)

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post